Management of Antibiotic-Resistant Helicobacter pylori Infection: Perspectives from Vietnam
- PMID: 31009957
- PMCID: PMC6743798
- DOI: 10.5009/gnl18137
Management of Antibiotic-Resistant Helicobacter pylori Infection: Perspectives from Vietnam
Abstract
Antibiotic resistance is the most important factor leading to the failure of eradication regimens. This review focuses on the prevalence of Helicobacter pylori primary and secondary resistance to clarithromycin, metronidazole, amoxicillin, levofloxacin, tetracycline, and multidrug in Vietnam. We searched the PubMed, EMBASE, Vietnamese National Knowledge Infrastructure, and Vietnamese Biomedical databases from January 2000 to December 2016. The search terms included the following: H. pylori infection, antibiotic (including clarithromycin, metronidazole, amoxicillin, levofloxacin, tetracycline, and multidrug) resistance in Vietnam. The data were summarized in an extraction table and analyzed manually. Finally, Excel 2007 software was used to create charts. Ten studies (three studies in English and seven in Vietnamese) were included in this review. A total of 308, 412, 523, 408, 399, and 268 H. pylori strains were included in this review to evaluate the prevalence of H. pylori primary resistance to amoxicillin, clarithromycin, metronidazole, levofloxacin, tetracycline, and multidrug resistance, respectively. Overall, the primary resistance rates of amoxicillin, clarithromycin, metronidazole, levofloxacin, tetracycline, and multidrug resistance were 15.0%, 34.1%, 69.4%, 27.9%, 17.9% and 48.8%, respectively. Secondary resistance rates of amoxicillin, clarithromycin, metronidazole, levofloxacin, tetracycline, and multidrug resistance were 9.5%, 74.9%, 61.5%, 45.7%, 23.5% and 62.3%, respectively. In Vietnam, primary and secondary resistance to H. pylori is increasing over time and affects the effectiveness of H. pylori eradication.
Keywords: Amoxicillin; Bismuth; Clarithromycin; Helicobacter pylori; Metronidazole.
Conflict of interest statement
No potential conflict of interest relevant to this article was reported.
Figures



Similar articles
-
Novel and Effective Therapeutic Regimens for Helicobacter pylori in an Era of Increasing Antibiotic Resistance.Front Cell Infect Microbiol. 2017 May 5;7:168. doi: 10.3389/fcimb.2017.00168. eCollection 2017. Front Cell Infect Microbiol. 2017. PMID: 28529929 Free PMC article. Review.
-
Primary Antibiotic Resistance of Helicobacter pylori in China.Dig Dis Sci. 2017 May;62(5):1146-1154. doi: 10.1007/s10620-017-4536-8. Epub 2017 Mar 17. Dig Dis Sci. 2017. PMID: 28315035 Review.
-
Triple therapy with high-dose proton-pump inhibitor, amoxicillin, and doxycycline is useless for Helicobacter pylori eradication: a proof-of-concept study.Helicobacter. 2014 Apr;19(2):90-7. doi: 10.1111/hel.12106. Epub 2014 Feb 10. Helicobacter. 2014. PMID: 24506175
-
[Primary antibiotic resistance of Helicobacter pylori strains and eradication rate according to gastroduodenal disease in Korea].Korean J Gastroenterol. 2011 Dec;58(2):74-81. doi: 10.4166/kjg.2011.58.2.74. Korean J Gastroenterol. 2011. PMID: 21873821 Korean.
-
The effect of previous eradication failure on antibiotic resistance of Helicobacter pylori: A retrospective study over 8 years in Beijing.Helicobacter. 2021 Aug;26(4):e12804. doi: 10.1111/hel.12804. Epub 2021 Apr 16. Helicobacter. 2021. PMID: 33860967
Cited by
-
Effects of Quadruple Therapy Combined with Probiotics on Helicobacter Pylori-Related Peptic Ulcer.Comput Math Methods Med. 2022 Oct 11;2022:1221190. doi: 10.1155/2022/1221190. eCollection 2022. Comput Math Methods Med. 2022. Retraction in: Comput Math Methods Med. 2023 Nov 29;2023:9795212. doi: 10.1155/2023/9795212. PMID: 36267315 Free PMC article. Retracted.
-
Current Worldwide Trends in Pediatric Helicobacter pylori Antimicrobial Resistance.Children (Basel). 2023 Feb 18;10(2):403. doi: 10.3390/children10020403. Children (Basel). 2023. PMID: 36832532 Free PMC article. Review.
-
H. pylori Infection and Colorectal Cancers by Anatomical Locations.Asian Pac J Cancer Prev. 2020 Aug 1;21(8):2431-2437. doi: 10.31557/APJCP.2020.21.8.2431. Asian Pac J Cancer Prev. 2020. PMID: 32856875 Free PMC article.
-
Vietnam Association of Gastroenterology (VNAGE) consensus on the management of Helicobacter pylori infection.Front Med (Lausanne). 2023 Jan 12;9:1065045. doi: 10.3389/fmed.2022.1065045. eCollection 2022. Front Med (Lausanne). 2023. PMID: 36714104 Free PMC article. Review.
-
Scope and Limitations of Current Antibiotic Therapies against Helicobacter pylori: Reviewing Amoxicillin Gastroretentive Formulations.Pharmaceutics. 2022 Jun 24;14(7):1340. doi: 10.3390/pharmaceutics14071340. Pharmaceutics. 2022. PMID: 35890236 Free PMC article. Review.
References
-
- Fukase K, Kato M, Kikuchi S, et al. Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial. Lancet. 2008;372:392–397. doi: 10.1016/S0140-6736(08)61159-9. - DOI - PubMed
-
- Dinis-Ribeiro M, Areia M, de Vries AC, et al. Management of precancerous conditions and lesions in the stomach (MAPS): guideline from the European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter Study Group (EHSG), European Society of Pathology (ESP), and the Sociedade Portuguesa de Endoscopia Digestiva (SPED) Endoscopy. 2012;44:74–94. doi: 10.1055/s-0031-1291491. - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical